Guyatt G H
J Chronic Dis. 1985;38(4):353-63. doi: 10.1016/0021-9681(85)90081-5.
Trials designed to establish the effectiveness of pharmacologic therapy in chronic heart failure illustrate methodologic problems associated with intervention trials in chronic disease. Early improvement in hemodynamic status or exercise capacity does not predict long-term changes, and hemodynamic variables do not correlate with exercise capacity. Mortality may not be a feasible outcome, suggesting that an adequate measure of quality of life is necessary to establish patient benefit. Care must be taken to ensure that subjects recruited are representative of the underlying population with respect to drug response. Need for cointervention can be dealt with by comparing only periods of comparable treatment, treating need for cointervention as a treatment failure, or using changes in non-study drugs as a measure of outcome. While cross-over designs can improve feasibility, the investigator runs the risk of inadequate followup and a time-treatment interaction. These issues must be considered in planning intervention trials in chronic disease.
旨在确定药物治疗对慢性心力衰竭有效性的试验揭示了与慢性病干预试验相关的方法学问题。血流动力学状态或运动能力的早期改善并不能预测长期变化,且血流动力学变量与运动能力无关。死亡率可能不是一个可行的结局指标,这表明需要有一个足够的生活质量衡量指标来确定对患者的益处。必须注意确保招募的受试者在药物反应方面能代表潜在人群。对于联合干预的需求,可以通过仅比较可比治疗期、将联合干预需求视为治疗失败或使用非研究药物的变化作为结局指标来处理。虽然交叉设计可以提高可行性,但研究者存在随访不足和时间-治疗相互作用的风险。在规划慢性病干预试验时必须考虑这些问题。